arrow
G

Giulio Cavalli

vita-salute san raffaele university
H指数:47
被引数:9,310

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

International nomenclature guidelines for the IL-1 family of cytokines and receptors
2024-03-183
PRE
Autoantibody-Mediated Depletion of IL-1RA in Still's Disease and Potential Impact of IL-1 Targeting Therapies
2024-01-172
OAAI
High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilation

高剂量anakinra除了标准护理外,还包括皮质类固醇治疗非侵入性通气治疗的严重新型冠状病毒肺炎患者

2023-09-190
PRE
Pediatric Recurrent Pericarditis: Appropriateness of the Standard of Care and Response to IL-1 Blockade
2023-05-016
OAAI
Testosterone in males with COVID-19: a 12-month cohort study
2022-10-2725
OA
Maladaptive Autophagy in the Pathogenesis of Autoimmune Epithelitis in Sjogren's Syndrome
2022-03-0127
PRE
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial (Sept, 10.1038/s41591-021-01499-z, 2021)
2021-10-0813
OAAI
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis

anakinra对新型冠状病毒肺炎患者死亡率的影响: 系统回顾和患者水平的荟萃分析

2021-10-01121
OAAI
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
2021-09-03360
OAAI
Testosterone in males with COVID-19: A 7-month cohort study
2021-08-3155
OA
Oncogene-induced senescence in hematopoietic progenitors features myeloid restricted hematopoiesis, chronic inflammation and histiocytosis
2021-07-2722
OAAI
The Spectrum of COVID-19-Associated Myocarditis: A Patient-Tailored Multidisciplinary Approach
2021-05-0414
OAAI
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation

呼吸障碍可预测新型冠状病毒肺炎重症肺炎和过度炎症患者对IL-1和IL-6阻滞的反应

2021-04-2933
OAAI
The anti-inflammatory cytokine interleukin-37 is an inhibitor of trained immunity
2021-04-0142
OAAI